Datapoint: CMS Finalizes Aduhelm Coverage Decision

CMS on April 7 finalized its narrow coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, limiting coverage to Medicare beneficiaries enrolled in clinical trials. The monoclonal antibody is the only drug approved to treat Alzheimer’s, and holds covered or better status for just 24% of all insured lives in the U.S.

SOURCE: MMIT Analytics, as of 4/12/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 6

Datapoint: Friday Health Plans to Shut Down

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 5

Datapoint: Kaiser Commits Up to $10M in Funding to Colorado System

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 1

Datapoint: FDA Approves Lexicon’s Heart Failure Drug

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today